Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Genetic Variation in the Progesterone Receptor Gene and Ovarian Cancer Risk
1 Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
2 Department of Epidemiology, Harvard School of Public Health, Boston, MA.
3 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.
4 Norris Cotton Cancer Center and the Departments of Community and Family Medicine and of Medicine, Dartmouth Medical School, Lebanon, NH.
5 Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Evidence suggests a role for progesterone in ovarian cancer development. Progesterone exerts its effect on target cells by interacting with its receptor. Thus, genetic variations that may cause alterations in the biologic functions of the progesterone receptor can potentially contribute to individual susceptibility to ovarian cancer. Using a population-based, case-control study, the authors genotyped four polymorphisms in the progesterone receptor gene (+44C/T, +331G/A, G393G, V660L) and inferred haplotypes in 987 ovarian cancer cases and 1,034 controls living in New Hampshire and eastern Massachusetts (May 1992–November 2002). Odds ratios and 95% confidence intervals were calculated to evaluate associations with ovarian cancer. No associations were observed between the +44C/T, +331G/A, and G393G polymorphisms and ovarian cancer. However, an inverse association was observed between the V660L variant and ovarian cancer (odds ratio = 0.70, 95% confidence interval: 0.57, 0.85). Associations remained after adjustment for potential confounders. Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92). Associations were similar after stratifying by ovarian cancer histologies and risk factors.
haplotypes; ovarian neoplasms; polymorphism, single nucleotide; receptors, progesterone
Abbreviations: CI, confidence interval; OR, odds ratio; rs, reference single nucleotide polymorphism; SNP, single nucleotide polymorphism.
Correspondence to Kathryn L. Terry, Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115 (e-mail: kterry{at}hsph.harvard.edu).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. L. Terry, S. S. Tworoger, M. A. Gates, D. W. Cramer, and S. E. Hankinson Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk Carcinogenesis, December 1, 2009; 30(12): 2042 - 2046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Ludwig, M. Murawska, G. Panek, A. Timorek, and J. Kupryjanczyk Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome Endocr. Relat. Cancer, September 1, 2009; 16(3): 1005 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Guoyang Luo, T. Morgan, M. O. Bahtiyar, V. V. Snegovskikh, F. Schatz, E. Kuczynski, E. F. Funai, A. T. Dulay, S.-T. J. Huang, C. S. Buhimschi, et al. Single Nucleotide Polymorphisms in the Human Progesterone Receptor Gene and Spontaneous Preterm Birth Reproductive Sciences, February 1, 2008; 15(2): 147 - 155. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Schildkraut, S. K. Murphy, R. T. Palmieri, E. Iversen, P. G. Moorman, Z. Huang, S. Halabi, B. Calingaert, A. Gusberg, J. R. Marks, et al. Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Z. Lu, S. E. Wardell, K. L. Burnstein, D. Defranco, P. J. Fuller, V. Giguere, R. B. Hochberg, L. McKay, J.-M. Renoir, N. L. Weigel, et al. International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors Pharmacol. Rev., December 1, 2006; 58(4): 782 - 797. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Risch, A. E. Bale, P. A. Beck, and W. Zheng PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1738 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dossus, F. Canzian, R. Kaaks, A. Boumertit, and E. Weiderpass No Association between Progesterone Receptor Gene +331G/A Polymorphism and Endometrial Cancer. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1415 - 1416. [Full Text] [PDF]
|
|